Expanding Tick and Itch Season Supports Momentum in Elanco Innovation, Meeting Pet Owner Demand for Health and Wellness Care
Elanco says warming temperatures are turning parasite and dermatology care into a year-round need, with its U.S. Pet Health price gains accelerating quarter-to-date (July and August) versus Q2. The company confirmed U.S. Pet Health remains on track for high-single digit to low double-digit growth in the second half of 2026, after both U.S.
Key figures
- Guidance
- U.S. Pet Health on track for high-single digit to low double-digit growth in the second half of 2026 (reaffirmed)
- Base portfolio trend
- improved from mid-to-high single digit declines in 2023-2024 to plus or minus low-single digit levels
- Delivery compliance uplift
- ~50% when pet owners shift to home delivery
- Otc parasiticide seasonality
- 52% of sales in H1, 48% in H2 (as of 2025)
- Credelio quattro clinics added qtd
- 1100
- Zenrelia europe share gain h1 2026
- 10 share points, 5x the competitive entrant
- Pet health organic cc growth h1 2026
- 9% YoY (both U.S. and International Pet Health)
- Us pet health reported growth h1 2026
- 9%
- International dermatology market growth h1 2026
- 9%
- International pet health reported growth h1 2026
- 15%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.